SCHEMBL31064271

SCHEMBL31064271

Fc1cc(-c2c(F)cccc2F)ccc1CN[C@@H]1CCCc2cccnc21

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.65
HDAC6 Q9UBN7 3/20 0.65
CXCR4 P61073 4/20 0.42
KMT2A Q03164 1/20 0.36
P2RX7 Q99572 8/20 0.36
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MAPK1 P28482 1/20 0.34
SLC40A1 Q9NP59 1/20 0.34
DHFR P00374 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31380403 0.84 HDAC1 (0.71) HDAC1HDAC6CXCR4KMT2AP2RX7
SCHEMBL31380388 0.83 HDAC1 (0.50) HDAC1HDAC6CXCR4HDAC8HDAC5
SCHEMBL30983220 0.83 HDAC1 (0.50) HDAC1HDAC6CXCR4HDAC8HDAC5
SCHEMBL31064357 0.81 HDAC1 (0.58) HDAC1HDAC6CXCR4P2RX7
SCHEMBL31064548 0.80 HDAC1 (0.43) HDAC1HDAC6P2RX7
SCHEMBL30983271 0.80 HDAC1 (0.56) HDAC1HDAC6CXCR4HDAC3HDAC4
SCHEMBL30983276 0.77 HDAC1 (0.47) HDAC1HDAC6CXCR4P2RX7HDAC8
SCHEMBL31380316 0.77 HDAC1 (0.43) HDAC1HDAC6CXCR4P2RX7HDAC8
SCHEMBL30983279 0.76 HDAC1 (0.49) HDAC1HDAC6CXCR4P2RX7HDAC8
SCHEMBL13909820 0.74 HDAC1 (0.76) HDAC1HDAC6CXCR4P2RX7KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688785-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 Beone Medicines I GmbH (CH) 2026-02-11 EP disclosed
US-20240368177-A1 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 BEIGENE SWITZERLAND GMBH (CH) 2024-11-07 US disclosed
WO-2024199255-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 BEIGENE SWITZERLAND GMBH (CH) 2024-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368177-A1 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 PRMT5, PRMT6, PRMT1 HDAC1 99/4885HDAC6 495/4885CXCR4 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.